The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

August 16, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
  • Do not start golimumab during an active infection. If an infection develops, monitor carefully and stop golimumab if the infection becomes serious.
  • For patients who develop a systemic illness on golimumab, consider empiric anti-fungal therapy for those who reside in or travel to regions where mycoses, such as histoplasmosis, coccidioidomycosis or blastomycosis, are endemic.
  • HBV many occur. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop golimumab and begin anti-viral therapy.
  • The incidence of lymphoma was seen more often than in the general U.S. population. Cases of other malignancies have been observed among patients receiving a TNFi.
  • Heart failure, worsening, or new onset, may occur. Stop golimumab if new or worsening symptoms occur.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Serious systemic hypersensitivity reactions, including anaphylaxis, may occur.
  • Lupus-like syndrome—stop golimumab if the syndrome develops.

Dosage & Administration

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Explore This Issue
August 2019

Golimumab is administered by SQ injection. The recommended dose is 50 mg once a month in combination with MTX.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Commentary

The FDA approval of golimumab injection was based on the results of three multi-center, randomized, double-blind, controlled trials that enrolled more than 1,500 patients. The most common adverse reactions (>5%) were upper respiratory tract infection, nasopharyngitis and injection site reactions.

Table 1: Rheumatoid Arthritis Medications at a Glance

(click for larger image) Table 1: Rheumatoid Arthritis Medications at a Glance
Key: MTX=methotrexate; PO=by mouth; SQ=subcutaneous; IV=intravenous; ALC=absolute lymphocyte count; ANC=absolute neutrophil count; ULN=upper limit of normal
*Approved by FDA, product has not launched

Golimumab (Simponi Aria):18 infusion

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (p. 14)

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Warnings & Precautions: Refer to *Simponi

Dosage & Administration

Golimumab is administered by IV infusion. The recommended dose is 2 mg/kg over 30 minutes at Weeks 0 and 4, then every eight weeks in combination with MTX.

Commentary

The FDA approval of golimumab injection for IV use was based on results from a clinical trial that enrolled nearly 600 patients. The trial showed the drug significantly improved the signs and symptoms of RA, improved physical function and slowed the progression of structural damage. The most common adverse reactions (≥3%) were upper respiratory tract infection, increased alanine aminotransferase, viral infection, increased aspartate aminotransferase, decreased neutrophil count, bronchitis, hypertension and rash.

Infliximab (Remicade):19 infusion

Biosimilar(s): infliximab-dyyb (Inflectra),20 infliximab-abda (Renflexis),21 infliximab-qbtx (Ixifi)22

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (p. 14) and

  • Fatal hepatosplenic T cell lymphoma (HSTCL) have been reported in patients treated with TNFi’s, post-marketing. All infliximab cases occurred in IBD patients, who were mostly adolescent or young adult males. All had received azathioprine or 6-mercaptopurine concomitantly with infliximab at or prior to diagnosis.

Warnings & Precautions

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: abatacept, adalimumab, anakinra, baricitinib, Certolizumab Pegol, etanercept, Golimumab, infliximab, rituximab, sarilumab, tocilizumab, TofacitinibIssue: August 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
  • Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)